Biopharmaceutical company Dyax has dosed the first subject in a Phase I study of fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, leveraging the company’s phage display technology platform.

The study will assess the safety and tolerability of single administration of DX-2930, developed by the company as a subcutaneous injection for the prevention of hereditary angioedema (HAE) attacks.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Dyax executive vice president and chief medical officer Dr Burt Adelman said that there is a significant requirement for an effective, safe and well tolerated prophylactic agent to treat HAE.

"DX-2930 is a highly potent, long-acting, fully human monoclonal antibody that binds specifically to active plasma kallikrein."

"DX-2930 is a highly potent, long-acting, fully human monoclonal antibody that binds specifically to active plasma kallikrein," Adelman added.

"We look forward to completing this study and moving forward rapidly with this important clinical program."

See Also:

The single-centre, randomised, double-blind, placebo-controlled study will assess the safety and tolerability of DX-2930 as well as characterise the pharmacokinetics (PK) of single, subcutaneous administrations of the investigational candidate in healthy subjects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study conducted at the clinical trials unit of Vince & Associates Clinical Research will enrol approximately 32 subjects into four ascending dose cohorts (n=8 per cohort) of DX-2930 or placebo.

Dyax president and CEO Gustav Christensen said, "We believe our knowledge of the plasma kallikrein pathway provides us with unique insight and a significant advantage in developing and commercialising this product candidate."